Applications of Proteomics in Ovarian Cancer: Dawn of a New Era

Ghose, Aruni; Gullapalli, Sri Vidya Niharika; Chohan, Naila; Bolina, Anita; Moschetta, Michele; Rassy, Elie El; Boussios, Stergios

doi:10.3390/proteomes10020016

Cited by 82 publications

(58 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, noninvasive clinical tests are needed to identify early disease in women, particularly women at higher risk. In pursuit of biomarkers of early disease detection, the field of proteomics has demonstrated the important clinical relevance of ovarian cancer diagnostics because the proteome closely mimics the dynamic state of human cells, tissues, and organs [ 11 ]. Furthermore, advanced proteomics technologies have helped drive our understanding of the human microbiome [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression

Mahoney

Chalise

Rahman

et al. 2022

Cancers

View full text Add to dashboard Cite

GI microbiota has been implicated in producing the inflammatory tumor microenvironment of several cancers. Women with ovarian cancer often report GI-related symptoms at diagnosis although minimal is known about the possible GI bacteria that may trigger pro-tumorigenic immune responses in early EOC. The purpose of this study was to investigate the influences of GI microbiota dysbiosis on serum inflammatory markers during EOC utilizing a rodent model. This experimental design consisted of C57BL/6 mice randomly assigned to either the microbiota dysbiosis group (n = 6) or control group (n = 5). The CD7BL/6 mice assigned to the microbiota dysbiosis group were administered a mixture of broad-spectrum antibiotics (bacitracin and neomycin) for 2 weeks. Both groups were injected intraperitoneally with mouse ovarian epithelial cells that induce ovarian tumorigenesis. Levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were assessed in the serum, and the composition of the GI microbiota in fecal samples was measured using 16S rRNA gene sequencing. Overall CRP serum levels were significantly lower and TNFα levels were significantly higher in the microbiota dysbiosis group compared to the control group. The abundances of microbiota that correlated with CRP serum levels in the combined groups were genus Parabacteroides, Roseburia, and Emergencia and species Ruminococcus faecis, Parabacteroides distasonis, Roseburia Faecis, and Emergencia timonensis. This study provides evidence to support for further investigation of the GI microbial profiles in patients at risk of EOC.

show abstract

Section: Introductionmentioning

confidence: 99%

Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression

Mahoney

Chalise

Rahman

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…especially severe adverse events, compared with chemotherapy alone ( 56 ). Current development of proteomics technology (mass spectrometry and protein array analysis) has deepened the identification of potential molecular signaling events and the proteomic characteristics of cervical and ovarian cancer, which facilitates the exploration of new therapeutic agents so as to reduce drug-resistance ( 57 ). In this meta-analysis, it was found that the incidence of the adverse events of grade 3 and above in the patients using pembrolizumab was 21.2%, mainly including tolerable liver dysfunction, hypothyroidism, neutropenia, anemia, decreased appetite, fatigue, and fever.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis

Lin

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAccording to current research, the objective response rate and overall survival of pembrolizumab in the treatment of several types of solid tumors have been significantly improved. Some high-quality clinical trials have studied the effect of applying pembrolizumab in treating cervical cancer. Multiple clinical trials have been conducted, and some of them have shown good results as expected. Therefore, we performed this meta-analysis on existing studies to reveal the efficacy and safety of pembrolizumab in treating cervical cancer.MethodsPubMed, Embase, Cochrane Library and Web of Science were searched for literatures published until October 31, 2021. Outcomes included complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), the best time to response (TTR), death rate, adverse events (AE).ResultsA total of 7 studies with 727 patients were included. The results were as follows: CR (0.027, 95%CI: 0.008-0.053), PR (0.104, 95% CI: 0.074-0.145), SD (0.190, 95% CI: 0.149-0.240), PD (0.541, 95% CI: 0.421-0.661). ORR was 0.155 (95% CI: 0.098-0.236) and DCR was 0.331 (95% CI: 0.277-0.385). OS was 10.23 months (95% CI: 8.96-11.50) and PFS was 4.27 months (95% CI: 1.57-6.96). TTR was 2.10 months (95%CI: 1.69-2.51). The 1-year death rate was 0.388 (95% CI: 0.230-0.574). Main adverse events included abnormal liver function, hypothyroidism, neutropenia, anemia, decreased appetite, fatigue, fever, etc. The total incidence of the adverse events of grade 3 and above was 0.212 (95% CI: 0.065-0.509).ConclusionsPembrolizumab provides significant benefits in response rate and survival for cervical cancer patients. The results from recent high-quality clinical trials are expected to validate these findings.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021291723.

show abstract

“…Jak/STAT 3 plays a role in tumor angiogenesis, survival, invasion, and chemoresistance. The inhibition of this pathway is shown to suppress tumor growth and progression [ 41 ]. The following figure illustrates the necroptosis-related signaling pathways ( Figure 1 ).…”

Section: Necroptosismentioning

confidence: 99%

Understanding Necroptosis in Pancreatic Diseases

Wang

Dong

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Intermediate between apoptosis and necrosis, necroptosis is a regulated caspase-independent programmed cell death that induces an inflammatory response and mediates cancer development. As our understanding improves, its role in the physiopathology of numerous diseases, including pancreatic diseases, has been reconsidered, and especially in pancreatitis and pancreatic cancer. However, the exact pathogenesis remains elusive, even though some studies have been conducted on these diseases. Its unique mechanisms of action in diseases are expected to bring prospects for the treatment of pancreatic diseases. Therefore, it is imperative to further explore its molecular mechanism in pancreatic diseases in order to identify novel therapeutic options. This article introduces recent related research on necroptosis and pancreatic diseases, explores necroptosis-related molecular pathways, and provides a theoretical foundation for new therapeutic targets for pancreatic diseases.

show abstract

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era

Cited by 82 publications

References 125 publications

Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression

Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression

Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis

Understanding Necroptosis in Pancreatic Diseases

Contact Info

Product

Resources

About